Loading…
Ovid Therapeutics Inc. is projected to rise to $2.90 by 2027, a +31% move from its current price of $2.22. OVID is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $2.16 | $2.22 | $2.29 | +0.05% |
| Aug 4 | $2.13 | $2.22 | $2.32 | +0.09% |
| Aug 5 | $2.11 | $2.22 | $2.34 | +0.14% |
| Aug 6 | $2.10 | $2.22 | $2.36 | +0.19% |
| Aug 7 | $2.08 | $2.23 | $2.38 | +0.24% |
| Aug 8 | $2.07 | $2.23 | $2.39 | +0.28% |
| Aug 9 | $2.06 | $2.23 | $2.41 | +0.33% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.06 | $2.23 | $2.41 | +0.33% |
| Week 2 | $2.00 | $2.23 | $2.50 | +0.66% |
| Week 3 | $1.96 | $2.24 | $2.57 | +1.00% |
| Week 4 | $1.92 | $2.25 | $2.63 | +1.33% |
| Week 5 | $1.89 | $2.26 | $2.69 | +1.67% |
| Week 6 | $1.87 | $2.26 | $2.75 | +2.01% |
| Week 7 | $1.84 | $2.27 | $2.80 | +2.35% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain disorders, including epilepsies and seizure-related neurological disorders in the United States.
The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
OVID is the stock for Ovid Therapeutics Inc. It trades with a current price of $2.31 and has a market cap of $430.21M, ranking 2983.
It is categorized in Healthcare.
The stock's technical picture includes a 50-day simple moving average of $2.51 and a 200-day simple moving average of $2.00.
The forecast price path shows a near-term neutral stance in 2026 with an avg of $2.31, bullish momentum through 2030 with an avg of $4.05, and long-term upside, with 2040 avg $12.60 and 2050 avg $22.40.
A major floor 16.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 24.3% above — a clean break opens room to run.
A major ceiling 33.3% above — clearing it would confirm fresh momentum.
Key OVID support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OVID market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.32 | Sell | $2.31 | Sell |
| MA 10 | $2.34 | Sell | $2.35 | Sell |
| MA 20 | $2.45 | Sell | $2.40 | Sell |
| MA 50 | $2.45 | Sell | $2.44 | Sell |
| MA 100 | $2.50 | Sell | $2.36 | Sell |
| MA 200 | $2.04 | Buy | $2.07 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.90 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -141.93 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -10.84 | Sell |
| Bollinger %B (20,2) | 0.09 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.20 | Sell |
| Awesome (5,34) | -0.13 | Sell |
| Ultimate (7,14,28) | 35.26 | Neutral |
| Momentum (10) | -0.22 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 2.29 | Sell |
| ADX (14) | 12.86 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is BULLISH, with RSI14 at 40.
SMA50 is $2.51 and SMA200 is $2.00.
Support is at $2.21 and resistance at $2.76; the 30-day range runs from $1.88 to $2.82.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.42 | $2.22 | $2.84 | 0% | Neutral | |
| $2.29 | $2.90 | $3.88 | +31% | Bullish | |
| $2.32 | $3.02 | $4.22 | +36% | Bullish | |
| $2.40 | $3.22 | $4.64 | +45% | Bullish | |
| $2.53 | $3.46 | $5.12 | +56% | Bullish | |
| $2.45 | $3.42 | $5.18 | +54% | Bullish | |
| $2.93 | $4.18 | $6.45 | +88% | Bullish | |
| $3.51 | $5.10 | $8.02 | +130% | Bullish | |
| $3.66 | $5.40 | $8.65 | +143% | Bullish | |
| $3.98 | $5.98 | $9.71 | +169% | Bullish | |
| $5.55 | $8.99 | $15.61 | +305% | Bullish | |
| $8.28 | $15.29 | $29.20 | +589% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.42 | $2.22 | $2.66 | +0.00% |
| September 2026 | $1.93 | $2.29 | $2.79 | +3.00% |
| October 2026 | $1.94 | $2.32 | $2.86 | +1.37% |
| November 2026 | $1.87 | $2.25 | $2.81 | -2.83% |
| December 2026 | $1.87 | $2.26 | $2.84 | +0.22% |
Click any year to see its month-by-month OVID forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, OVID is projected to trade between $1.42 and $2.84, averaging $2.22 — a potential gain of 0% from today's $2.22. A consolidation phase looks the most probable path here.
Ovid Therapeutics Inc.'s 2027 outlook centres on $2.90, within a $2.29 to $3.88 range. That is up +31% on the projected 2026 average. That marks a +31% change versus current levels. Momentum favours further upside here.
By 2028, OVID could reach as high as $4.22, with a base case around $3.02 and support toward $2.32 — roughly +36% from $2.22. Buyers look set to stay in control over this stretch.
Expect OVID to range from $2.40 to $4.64 through 2029. The $3.22 average target implies a +45% move from current prices. That is up +6% on the projected 2028 average. Momentum favours further upside here.
The OVID price prediction for 2030 points to an average of $3.46 (low $2.53, high $5.12) — a potential gain of +56% on today's $2.22. Buyers look set to stay in control over this stretch.
In 2031, OVID is projected to trade between $2.45 and $5.18, averaging $3.42 — a potential gain of +54% from today's $2.22. That is -1% versus the projected 2030 average. Momentum favours further upside here.
Ovid Therapeutics Inc.'s 2032 outlook centres on $4.18, within a $2.93 to $6.45 range. That is up +22% on the projected 2031 average. That marks a +88% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, OVID could reach as high as $8.02, with a base case around $5.10 and support toward $3.51 — roughly +130% from $2.22. Momentum favours further upside here.
Expect OVID to range from $3.66 to $8.65 through 2034. The $5.40 average target implies a +143% move from current prices. That is up +6% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The OVID price prediction for 2035 points to an average of $5.98 (low $3.98, high $9.71) — a potential gain of +169% on today's $2.22. Momentum favours further upside here.
In 2040, OVID is projected to trade between $5.55 and $15.61, averaging $8.99 — a potential gain of +305% from today's $2.22. That is up +50% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Ovid Therapeutics Inc.'s 2050 outlook centres on $15.29, within a $8.28 to $29.20 range. That is up +70% on the projected 2040 average. That marks a +589% change versus current levels. Momentum favours further upside here.
Investing $1,000 in OVID today (≈ 450.45045 OVID) could be worth
$6,886.64
+$5,886.64 (+589%) by 2050 · US Dollar
Based on the average projected OVID price of $15.29 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OVIDwould be worth at today's price.
$1,000 invested in OVID on Jul 31, 2025 (≈ 2,000 OVID) would be worth
$4,440
+$3,440 (+344.0%) today · 4.44× · US Dollar
Based on a OVID entry price of $0.5 vs. today's $2.22.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.33 | $952.79 | -4.7% |
| 1 month ago | $2.68 | $828.36 | -17.2% |
| 3 months ago | $2.79 | $795.7 | -20.4% |
| 6 months ago | $1.51 | $1,470.2 | +47.0% |
| 1 year ago | $0.5 | $4,440 | +344.0% |
| All time (5.0y) ago | $3.7 | $600 | -40.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OVID forecast.
Our base-case forecast reaches $4.40 around 2033.
Implied market cap at $4.40: $821.22M
The multi-year forecast shows a bullish trend with rising averages from 2026 through 2035; the 2026 avg price is $2.31, the 2030 avg price is $4.05, and the 2035 avg price is $7.90.
In 2040 the avg price is $12.60 and in 2050 it is $22.40; max forecasts reach $22.12 in 2040 and $43.36 in 2050.
ROI rises from 0 in 2026 to 75.5 in 2030 and 872 in 2050; sentiment remains BULLISH across these years.
These are estimates and not guarantees; actual results may differ.
Tap a question to reveal the answer.
Avg $4.05; Min $2.93; Max $6.03; ROI 75.5; Sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward, with rising averages to 2030 ($4.05) and 2050 ($22.40); maxs reach $43.36 and ROI rises to 872. Note that 2026 is Neutral and these are estimates.
Yes, the 2033 max is $10.40.
Avg $12.60; Min $7.67; Max $22.12; ROI 446.5; Sentiment BULLISH.
Avg $22.40; Min $11.89; Max $43.36; ROI 872; Sentiment BULLISH.
Ovid Therapeutics Inc. Community Discussion
0Share your Ovid Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.